Just one dose of psilocybin significantly improved depression symptoms and functional disability in patients with major depressive disorder (MDD), a randomized trial found. Administered with ...
1 Montgomery -Åsberg Depression Rating Scale (MADRS) scale range 0-60, higher scores indicating more severe depression. 2 Least Squares (LS) Means are means estimated from a linear model that are ...
Psilocybin therapy reduced depression symptoms in clinicians who developed these symptoms after frontline clinical work during the COVID-19 pandemic, a small randomized trial showed. At day 28, the ...
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg ...
Updated Part B results demonstrated sustained efficacy for COMP360 psilocybin 25mg, maintaining symptom severity reductions through week 26 after just 1 or 2 doses.
A biopharmaceutical company this week unveiled the results of a clinical trial it says showcases the potential of psychedelics as a mental health treatment. The findings come via Cybin, a Canadian ...
BioWorld - Friday, December 8, 2023 See today's BioWorld Home » Size MADRS, agency says; shortened scale could foil Alkermes' MDD adcom bid X Upgrade your daily dose of biopharma and medtech news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results